DELINEATE试验:前列腺癌瘤内主结节标准与中度大分割剂量递增的疗效与毒性
DELINEATE是一项单中心前瞻性2期多队列研究,纳入局限期前列腺癌中高危患者,比较标准分割(74 Gy/37次)与中度大分割(60 Gy/20次)放疗并同步整合推量至多参数MRI可见的前列腺内主结节(分别推量至82 Gy和67 Gy)。主要终点为1年晚期RTOG直肠毒性,结果显示两组晚期2级及以上直肠毒性分别为3.6%和8%,泌尿毒性分别为0%和10%,无晚期3级直肠毒性,提示标准与中度大分割方案下同步推量可行且毒性可控。
要点
- 标准分割组1年晚期RTOG≥2级直肠毒性3.6%、泌尿毒性0%。
- 中度大分割组1年晚期RTOG≥2级直肠毒性8%、泌尿毒性10%。
- 两组均无晚期3级直肠毒性报告。
核心结论
- 标准分割和中度大分割放疗中同步整合推量至前列腺内主结节均可行,直肠和泌尿生殖毒性可与无瘤内推量的当代系列相当。
研究设计与样本
- DELINEATE为单中心前瞻性2期多队列研究,包括标准分割队列A(74 Gy/37次)和中度大分割队列B(60 Gy/20次),均采用图像引导调强放疗。
- 纳入NCCN中危和高危局限期前列腺癌患者,对多参数MRI可见病灶给予同步整合推量,队列A推量至82 Gy,队列B推量至67 Gy。
- 队列A治疗55例,队列B治疗158例,本计划分析纳入队列B中前50例连续治疗患者。
- 主要终点为1年晚期RTOG直肠毒性,次要终点包括其他时间点临床医生报告和患者报告的急性和晚期毒性,以及队列A的生化无复发生存。
- 队列A中位随访74.5个月,队列B中位随访52.0个月。
主要发现
- 队列A和队列B分别有27%和40%的患者为NCCN高危疾病。
- 队列A 1年累积RTOG≥2级直肠毒性发生率为3.6%,泌尿毒性为0%;队列B分别为8%和10%。
- 两个队列均未报告晚期3级直肠毒性。
- 队列A中55例患者有4例(7%)出现生化复发。
临床怎么用
- 对于局限期中高危前列腺癌,可在标准分割或中度大分割图像引导调强放疗基础上,对多参数MRI可见的前列腺内主结节实施同步整合推量。
- 实施瘤内推量时,直肠和泌尿生殖毒性总体可控,但需关注大分割方案下晚期2级及以上泌尿毒性(10%)和直肠毒性(8%)。
局限性
- 本研究为单中心前瞻性2期研究,样本量有限,队列B计划分析仅纳入前50例连续治疗患者。
- 队列B中位随访52.0个月,较队列A的74.5个月短,晚期毒性评估时间尚不充分。
- 原文未报告随机对照比较,无法直接比较推量与无推量的疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report a planned analysis of the efficacy and toxicity of dose escalation to the intraprostatic dominant nodule identified on multiparametric magnetic resonance imaging using standard and hypofractionated external beam radiation therapy. METHODS AND MATERIALS: DELINEATE is a single centre prospective phase 2 multicohort study including standard (cohort A: 74 Gy in 37 fractions) and moderately hypofractionated (cohort B: 60 Gy in 20 fractions) prostate image guided intensity modulated radiation therapy in patients with National Comprehensive Cancer Network intermediate- and high-risk disease. Patients received an integrated boost of 82 Gy (cohort A) and 67 Gy (cohort B) to lesions visible on multiparametric magnetic resonance imaging. Fifty-five patients were treated in cohort A, and 158 patients were treated in cohort B; the first 50 sequentially treated patients in cohort B were included in this planned analysis. The primary endpoint was late Radiation Therapy Oncology Group rectal toxicity at 1 year. Secondary endpoints included acute and late toxicity measured with clinician- and patient-reported outcomes at other time points and biochemical relapse-free survival for cohort A. Median follow-up was 74.5 months for cohort A and 52.0 months for cohort B. RESULTS: In cohorts A and B, 27% and 40% of patients, respectively, were classified as having National Comprehensive Cancer Network high-risk disease. The cumulative 1-year incidence of Radiation Therapy Oncology Group grade 2 or worse rectal and urinary toxicity was 3.6% and 0% in cohort A and 8% and 10% in cohort B, respectively. There was no reported late grade 3 rectal toxicity in either cohort. Within cohort A, 4 of 55 (7%) patients had biochemical relapse. CONCLUSIONS: Delivery of a simultaneous integrated boost to intraprostatic dominant nodules is feasible in prostate radiation therapy using standard and moderately hypofractionated regimens, with rectal and genitourinary toxicity comparable to contemporary series without an intraprostatic boost.
引用
- Murray JR, Tree AC, Alexander EJ, et al. Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31812718. doi:10.1016/j.ijrobp.2019.11.402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。